29 results on '"Garassino, M.C."'
Search Results
2. 34P Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC
3. OA01.05 Three-year Outcomes per PD-L1 Status and Continued Cemiplimab Beyond Progression + Chemotherapy: EMPOWER-Lung 1
4. PP01.01 PEOPLE (NTC03447678), a Phase II Trial to Test Biomarkers of Response to Pembrolizumab as First-Line Treatment in Advanced NSCLC Patients with PD-L1>50%
5. PPD02.03 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients From VISION Cohorts A and C
6. P50.06 First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate
7. P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy
8. P40.19 Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
9. P40.08 Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors
10. MA16.06 Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN
11. MA12.03 A Thoracic Cancers International COVID 19 Collaboration Survey on Patients’ Perceptions of COVID-19 (Teravolt-Paper)
12. 184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)
13. 157P Tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION cohort A
14. 133P Drug-drug interactions (DDIs) in non-small cell lung cancer during chemotherapy-immunotherapy treatment
15. 79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
16. 78MO Early safety assessment of durvalumab after sCRT in patients with stage III, unresectable NSCLC (PACIFIC-6)
17. P85.01 Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC
18. P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN
19. P33.01 Circulating Extracellular Vesicles as Biomarkers for Immune-Checkpoint Inhibitors in Advanced NSCLC
20. P30.02 Assessing SIADH (Syndrome of Inapproriate Antidiuretic Hormone Secretion) Management and Outcome Among Lung Cancer Patients: The Assert Trial
21. P09.18 COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT)
22. MA11.05 Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A
23. MA11.04 Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients
24. FP14.09 Tepotinib Safety in MET Exon 14 (METex14) Skipping NSCLC: Updated Results from the VISION Trial
25. FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
26. PUL01.03 Effect of Tumor Size Change and Duration of Response on OS With First-Line Pembrolizumab Plus Pemetrexed-platinum For Metastatic Nonsquamous Non‒Small-Cell Lung Cancer
27. PD2.02 Pembrolizumab plus Pemetrexed-Platinum for Patients with Metastatic Nonsquamous NSCLC and Liver or Brain Metastases: Results from KEYNOTE-189
28. O.02 Long-term Survival Outcomes with Nivolumab (NIVO) in Pts with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC): Impact of Early Disease Control and Response
29. O.03 KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab + Chemotherapy for Metastatic Nonsquamous NSCLC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.